Repligen CFO Jason Garland Sells Shares
CFO Jason Garland sold 733 shares of Repligen Corporation on June 25 under a planned sale.
Key Points
- Repligen CFO Jason Garland sold 733 shares on June 25, valued at $106,285, at an average price of $145 per share.
- Repligen Corporation trades around $147.01 with a market cap of $8.29 billion and a P/E ratio of 161.5.
- Analysts maintain a buy rating for Repligen, with price targets ranging from $142 to $220.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Repligen Corporation's CFO, Jason Garland, recently sold 733 shares of the company on June 25, 2026. The shares were sold at an average price of $145 each, amounting to a total transaction value of $106,285. This sale was part of a planned transaction, as disclosed in the filing.
Insider Buying and Selling at Repligen Corporation
In addition to Jason Garland's recent sale, several other insiders have made transactions. On May 14, 2026, Carrie Eglinton Manner, Nicolas Barthelemy, Martin Madaus, Glenn Muir, and Karen Dawes each bought shares of Repligen. These purchases were not part of any pre-arranged plan.
Repligen Corporation Stock Down 16.6%
Shares of NasdaqGS:RGEN traded near $147.01 on Saturday. Repligen Corporation, with a market cap of $8.29 billion, has a P/E ratio of 161.5 and a forward P/E of 57.7. The company's beta is 1.081, indicating moderate volatility compared to the market. The stock's 52-week range is between $100.99 and $175.77, with a 50-day moving average of $122.61 and a 200-day moving average of $138.61.
$RGEN stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts continue to show confidence in Repligen with several maintaining buy ratings. On June 3, 2026, HSBC maintained its buy rating with a target price of $150. Wolfe Research assumed coverage with a buy rating and a target of $145 on June 2. RBC Capital reinstated its buy rating with a target of $160 on May 15. The consensus among 19 analysts is a buy recommendation, with an average target price of $176.11.
About Repligen Corporation
Repligen Corporation, headquartered in Waltham, Massachusetts, is a life sciences company that focuses on developing and commercializing bioprocessing technologies and systems. The company serves life sciences, biopharmaceutical, and diagnostics companies worldwide. Repligen's product offerings include chromatography systems, filtration products, and process analytics tools. The company was incorporated in 1981 and is led by CEO Olivier Loeillot.
Bottom Line
Jason Garland's recent sale of Repligen shares was part of a planned transaction, reflecting his personal financial strategy rather than a change in the company's outlook. Repligen remains a significant player in the healthcare sector, and its stock continues to be a topic of interest for analysts and investors alike. As always, insider transactions provide insight into executive actions but should be considered alongside other factors. Investors should remember that 13F filings and insider reports are historical and may not reflect current positions.
Get Repligen Corporation alerts
New 13F filings, insider trades, and analyst moves on $RGEN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.